FOI 23/177 ADR reports for Northern Ireland

REQUEST
7 March 2023

This foi has been answered in a completely different format to the previous one which makes it very hard to understand.
Also I believe you have misinterpreted my request or perhaps I di not make my request clear enough.

1) I am requesting the total number of suspected deaths from the covid 19 vaccines in Northern Ireland from the start of the rollout to the present day ?
Previous figures supplied by yourselves were:
Pfizer 12
AstraZeneca 35
Moderna *
Brand Unspecified 0

2) I am requesting the total number of non-serious and serious including fatal figures in Northern Ireland from the start of the rollout to the present day ?
Previous figure supplied by yourselves had a one total figure for Pfizer in table 5 now you have supplied 2 different figures for Pfizer and it is a bit confusing.

Please can you supply the information I have requested in the same format as the September 2022 response.

Total number of deaths from the start of the rollout until present day by vaccine manufacturers and then a separate box chart whereby these numbers are split into age groups.

Total number of serious injuries from these vaccines from the start of the rollout until present day by vaccines manufacturers and then a separate box charts showing same by age group.

MHRA RESPONSE
31 March 2023

Thank you for email dated March 7th and please accept my apologies that the format has changed between responses or if we misinterpreted your request. The decision was made to alter the format given much of the information we would have provided to you in the original format would have been censored due to the number of reports being less than 5. We want to provide you with data that will be helpful and as such we wanted to send this for clarification on your most recent request so that we may fulfil your enquiry as well as possible.

Regarding your question relating to there being two separate figures for Pfizer, since your initial request the MHRA have approved bivalent COVID-19 vaccines for Moderna and Pfizer. These vaccines are effective against two strains of COVID-19,

original and omicron. As the bivalent vaccines are distinct from the original vaccines the data regarding ADR reports has also been kept distinct. These bivalent vaccines have been used in the Autumn 2022 booster campaign.

Based on your email dated 7th March, please would you be able to clarify if updates to the below two tables which were provided in FOI 22/982 is what you require? These tables would be updated to include data from the entire length of the vaccination programme up to the date we extract the data from our database. It would also include the bivalent Pfizer/BioNTech and Moderna vaccines.

Question 1
Number of UK ADR reports from Northern Ireland for the COVID-19 vaccines where there was a fatal outcome.

Vaccine	Fatal
COVID-19 Vaccine Pfizer/BioNTech	12
COVID-19 Vaccine AstraZeneca	35
COVID-19 Vaccine Moderna	*
COVID-19 Vaccine Brand Unspecified	0

Question 2
Number of UK ADR reports from Northern Ireland received for a COVID-19 vaccine by seriousness up to and including 29th September 2022.

Vaccine	Non-Serious	Serious (incl. fatal)
COVID-19 Vaccine Pfizer/BioNTech	906	2290
COVID-19 Vaccine AstraZeneca	597	2511
COVID-19 Vaccine Moderna	46	137
COVID-19 Vaccine Brand Unspecified	5	18

To note we can provide you with the tables (tables 2-4 in response 22/089) showing the number of reports per month for each age group. However, when we have looked at this, the majority of the data from September 2022 broken drown in this fashion is censored due to there being less than 5 reports. The number of reports would only be displayed for four age group-month combinations across each vaccine, will all other cells in the tables being censored.

I hope the clarification from us on this request is clear and please let me know if this is what you require and if so, we will update the figures and get back to you promptly. If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.
For information on the reproduction or re-use of MHRA information, please visit https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF